What is the current performance of HM1?
HM1’s performance metrics, including portfolio returns, are updated regularly. You can find the latest performance reports in our InvestorHub here.
How can I invest in HM1?
HM1 shares can be purchased through the ASX using the ticker code "HM1." You can invest via a stockbroker, financial advisor, or an online brokerage account.
What are the benefits of investing in HM1?
HM1 provides investors with:
- Access to high-conviction ideas from leading fund managers, many of whom are typically unavailable to retail investors.
- A professionally managed portfolio delivering both growth and income.
- The opportunity to support Australian medical research while building your financial future.
How does HM1 pay dividends?
Yes, HM1’s dividend policy is to pay consistent, fully franked dividends to its shareholders. Dividend payments are made semi-annually, subject to the performance of the portfolio. More information and key dates about upcoming dividends are available in our InvestorHub here.
What is the Dividend Reinvestment Plan (DRP)?
HM1 offers a Dividend Reinvestment Plan (DRP), allowing shareholders to reinvest their dividends into additional shares rather than receiving cash payments. This enables investors to compound their investment over time. Information on how to participate in the DRP is available in the InvestorHub.
What is the typical portfolio structure?
The portfolio consists of 25–35 securities:
- 65% allocated to up to 21 high-conviction ideas recommended by our Core Fund Managers.
- 35% allocated to ideas presented by Conference Fund Managers at the annual Sohn Hearts & Minds Conference. These stocks are held for a 12 month investment horizon.
How are the Core Fund Managers selected?
Core Fund Managers are selected based on their proven track record, expertise in global equities, and ability to provide high conviction investment ideas. Each manager commits to a minimum three-year term and contributes on a pro bono basis.
How are the Conference Fund Managers selected?
Conference Fund Managers are selected through a thorough process led by the Conference Fund Manager Selection Committee. This process evaluates their expertise, track record, and willingness to contribute high conviction ideas to HM1’s portfolio.
What fees does HM1 charge?
HM1 does not charge traditional management or performance fees. Instead, fund managers and service providers typically contribute their services on a pro bono basis, allowing 1.5% of Net Tangible Assets (NTA) to be donated to medical research annually.
How often is the portfolio reviewed or updated?
The portfolio is actively monitored and overseen by HM1’s Chief Investment Officer, with oversight and support from the HM1 Investment Committee. The Investment Committee meets quarterly to formally review the portfolio to ensure alignment with HM1’s strategy.
Additionally, one-third of the portfolio is refreshed annually based on recommendations from Conference Fund Managers.
